Floatz logo

Omacetaxine

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

Roswell Park Cancer InstitutePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Daunorubicin
Institut de Recherches Internationales Servier
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
ag-120
Institut de Recherches Internationales Servier
Phase 3BB

View all 50 →

Same molecule, other indications

Omacetaxine is also rated in:

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
Elderly Patients (60-75 Years)Dormant
B
Indicative ·
60 / 100
View asset →
Induction ChemotherapyDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →